Titan Pharmaceuticals, TTNP, Profile, Summary
Titan Pharmaceuticals | TTNP | Profile | Summary
Titan Pharmaceuticals, Inc. is a biopharmaceutical Company developing proprietary therapeutics primarily for the treatment of serious medical disorders.
Titan’s principal asset is Probuphine®, the first slow-release implant formulation of buprenorphine hydrochloride (“buprenorphine”), designed to maintain a stable, round-the-clock blood level of the medicine in patients for up to six months following a single treatment. The outpatient treatment of opioid dependence with daily dosed sublingual buprenorphine formulations represents a $1.3 billion market in the U.S., and a seven day transdermal patch formulation of buprenorphine for the treatment of chronic pain was launched in the U.S. in 2011. This novel implant formulation is inserted subdermally in a patient’s upper arm providing continuous medication, and has the potential to enhance patient compliance to treatment, and limit diversion for illicit use and accidental exposure to the sublingual formulations.
The New Drug Application (NDA) was submitted to the FDA in October, 2012 seeking approval for treatment of opioid dependence. In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $50 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $130 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties.
Probuphine is the first product to utilize ProNeura™, a novel, proprietary, long-term drug delivery technology. The ProNeura technology has the potential to be used in developing products for the treatment of other chronic conditions, such as Parkinson’s disease, where maintaining stable, round-the-clock blood levels of a drug can benefit the patient and improve medical outcomes.
Continuous Drug Delivery Technology
The continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (“EVA”) and a drug substance. The resulting product is a solid matrix that is placed subcutaneously, normally in the inner part of the upper arm in a simple office procedure, and is removed in a similar manner at the end of the treatment period. The drug substance is released slowly, at continuous levels, through the process of dissolution. This results in a stable blood level similar to intravenous administration. Such long-term, linear release characteristics are generally desirable as this avoids peak and trough level dosing that poses problems for many Central Nervous System (“CNS”) and other disease settings.
This continuous drug delivery technology was developed to address the need for a simple, practical method to potentially provide continuous drug administration on an outpatient basis over extended periods of up to 6-12 months. In addition to Probuphine, which is the first product to complete clinical testing that has utilized this proprietary continuous drug delivery technology, Titan has conducted initial non-clinical studies with long-term delivery of dopamine agonists demonstrating the potential of this product in the treatment of Parkinson’s disease in non-clinical models of the disease.
Strategic Alliances
In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $50 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $130 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties.
Novartis Pharma, AG, has licensed the rights to commercialize Fanapt in the U.S. and Canada, and commenced marketing the product in the U.S. in Q1, 2010. Titan is entitled to receive a royalty of 8-10% on the global net sales of this product. Titan does not incur any expenses related to this product.
Source: Titan Pharmaceuticals, OxBridge Research, Daily Stock Deals, OTC King. PSM
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks. PennyStockMonster.com is an OxBridge affiliate/partner website.
Disclosure/Disclaimer:- OxBridge Research publishes sponsored research reports, advertorials and corporate profiles on its portal and several other websites/blogs, including this website/blog, owned and operated by OxBridge and/or its affiliates. OxBridge Research is not a Broker Dealer or a Registered Financial Adviser in any jurisdiction, whatsoever. All the information published on its website(s) and/or distributed to its members via various electronic means is for general awareness and entertainment purpose only. OxBridge urges investors to do their own due diligence and consult with their financial adviser prior to making any investment decision. We are expecting a payment from the company/a third party/shareholder. We receive compensation from companies for providing various IR services, including publication, advertisement,and social media awareness, therefore our views/opinion are inherently biased. Please read the full disclosure/disclaimer, if you need assistance contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it
OxbridgeResearch.com, All Rights Reserved. Trademarks/logos are of their respective owners.
It's YOUR money - Invest WISELY TM
$20,000 in just 5 months, on a thousand shares, MAKO made members rich! Deep insight, Real Results revealed!
You could have made a whopping $20,000 in just 5 month! if you had bought only a thousand shares! Deep insight, Real Results revealed! MAKO made our members rich!
See the original post here
|
MAKO, Mako Surgical, trading at $10, could be a huge winner |
Note: PSM is an OxBridge affiliate/partner, content reprinted with permission. Editor
|
Written by Administrator |
|
Friday, 26 April 2013 10:24 |
|
MAKO Surgical (MAKO), a medical device company, markets its advanced robotic arm solution, joint specific applications for the knee and hip, and orthopedic implants for orthopedic procedures in the United States and internationally. The company offers MAKOplasty, a restorative surgical solution that enables orthopedic surgeons to treat patient specific osteoarthritic disease. It also provides robotic arm interactive orthopedic system (RIO) consisting of a tactile robotic arm utilizing an integrated bone cutting instrument; and a patient specific visualization component, which offers pre-operative and intra-operative guidance to the orthopedic surgeon, enabling tissue sparing bone removal, and accurate implant insertion and alignment. In addition, the company offers MAKOplasty partial knee arthroplasty (PKA) products that enable resurfacing of one or two specific diseased compartments of the joint, preserving more soft tissue and healthy bone of the knee; and MAKOplasty Total Hip Arthroplasty, a surgical solution that enables orthopedic surgeons to perform total hip arthroplasty. Further, it provides RESTORIS onlay knee implant system for patients who lack tibia sclerotic bone beds; RESTORIS MCK unicompartmental and bicompartmental knee implant system to support the tissue and bone sparing goals of MAKOplasty PKA; and RESTORIS family of hip implant systems. The company markets and sells its products through direct sales force, as well as through independent orthopedic product agents and distributors. MAKO Surgical Corp. was founded in 2004 and is headquartered in Fort Lauderdale, Florida. Sources: company, OxBridge Research, Daily Stock Deals
|
China Pharma, CPHI, Profile, Summary
China Pharma| CPHI| Profile| Summary
China Pharma, CPHI, is a specialty pharmaceutical company that develops, manufactures and markets generic and brand pharmaceutical products for both western and traditional Chinese medicines in China. Currently, the company’s main focus for its therapeutics includes CNS, cardiovascular, cerebro-vascular, wound recovery, digestive disease, and infectious diseases. Its products are sold in 30 provinces, municipalities, and autonomous regions. The Company has 16 sales offices and approximately 680 proxy agents in the whole country.
China Pharma is located in the tax-free industrial zone of Haikou, Hainan Province, with manufacturing facility of 8,000 square meters. The Company is equipped with eight GMP(Good Manufacturing Practice) certified production lines and has the capacity to produce drugs in a variety of delivery mechanisms including freeze dried(lyophilized injectables), capsules, tablets, granules, injectables, and oral fluids(suspension). The company is positioning itself to benefit from China’s rapidly growing pharmaceutical market as it expands its product portfolio.
Research & Development
China Pharma develops generic products based on market demand by combining internal product development, strategic alliances with partners and collaborations of its products and businesses. The Company targets off-patent drugs with cumulative global sales over $1billion. Under Chinese law, China Pharma is able to obtain exclusivity protection for three or more years for new generics it brings to market. The disease areas China Pharma is currently focusing on are: neurology, hyperlipidemia and cardiovascular disease, hyperglycemia and diabetes , hypertension, and infectious diseases. China Pharma has built strong research and development partnerships with the following elite institutions in China and retains the ownership rights to all resulting intellectual property of products.
Modern Manufacturing Facilities
China Pharma has scalable GMP-certified manufacturing facilities with eight different modern production lines. These facilities passed the GMP-certification when it was first introduced in 2003 and passed the latest round in 2008. The GMP-certification is repeated every five years.
In 2008 the Company invested $3.0 million to increase capacity of the dry powder line. China Pharma’s cutting edge production lines can manufacture products in the following forms of delivery: tablets; capsules; injectables; granules; oral fluids (suspension); and freeze dried (lyophilized injectables). Its production capacity fully satisfies the needs of the current portfolio.
→ -The company received GMP certification in 2003
→ - Recognized as “The Best Enterprise for Storing SARS Medicine” by Hainan Food and Drug Administration.
→ -Received national key new products certificate for Buflomedil Hydrochloride by the State Science and Technology Department, State Taxation Bureau, Ministry of Commerce, State Bureau of Quality Supervision, Inspection and Quarantine, and State Environmental Protection Bureau.
→ -Designated as key technology project in Hainan for Buflomedil Hydrochloride by
Haikou Municipality.
Source: China Pharma, OxBridge Research, Daily Stock Deals, OTC King, PSM
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks. PennyStockMonster.com is an OxBridge affiliate/partner website.
Disclosure/Disclaimer:- OxBridge Research publishes sponsored research reports, advertorials and corporate profiles on its portal and several other websites/blogs, including this website/blog, owned and operated by OxBridge and/or its affiliates. OxBridge Research is not a Broker Dealer or a Registered Financial Adviser in any jurisdiction, whatsoever. All the information published on its website(s) and/or distributed to its members via various electronic means is for general awareness and entertainment purpose only. OxBridge urges investors to do their own due diligence and consult with their financial adviser prior to making any investment decision. We are expecting a payment from the company/a third party/shareholder. We receive compensation from companies for providing various IR services, including publication, advertisement,and social media awareness, therefore our views/opinion are inherently biased. Please read the full disclosure/disclaimer, if you need assistance contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it
OxbridgeResearch.com, All Rights Reserved. Trademarks/logos are of their respective owners.
It's YOUR money - Invest WISELY TM
Penny Stock Monster
Feed Entries
